The Drug Disease Model Resources (DDMoRe) Consortium has been created to improve the quality, efficiency and cost effectiveness of Model-Informed Drug Discovery & Development. it is a five-year project of the Innovative Medicines Initiative (IMI, www.imi.europa.eu) with 26 stakeholders from the pharmaceutical industry, small and medium-sized enterprises and academic research organizations.
Mango Solutions is proud to be a member of this Consortium and announce that a milestone was reached on 11th December 2015 with the first Public Release of the DDMoRe Interoperability Framework.
The DDMoRe Interoperability Framework is an integrated set of new standards and connectors for many common programming tools and languages currently used by researchers performing Modelling and Simulation. It enables a major transformation towards more productive use of computational models as a basis for informed, quantitative decision-making in research and development for new medicines. Two of the new integration standards developed by the Consortium – the Model Description Language (MDL) and Pharmacometric Markup Language (PharmML) – are at the heart of the Interoperability Framework. Automatic translators between these two languages and the languages used by existing tools (e.g. NM-TRAN for NONMEM), result in a platform that can be utilised for models and knowledge sharing, based on standards to ensure consistency of evidence. Academia, industries and health authorities can rely on this platform in making decisions about development, approval of new medicines and improvement of therapy with existing drugs.
Mango’s involvement within the Consortium covers the specification and development of a number of the software components comprising the Interoperability Framework, including specific responsibility for designing and implementing the PharmML to NM-TRAN language converter (allowing seamless integration of NONMEM), and an R package to manipulate objects defined in the MDL.
For the remaining 8 months of the project, Mango will continue to be an active member within the Consortium, both by adding functionality to the existing components as well as developing new software for upcoming features such as the support for adding metadata and annotations to models and allowing repeatable analysis execution within a standards-based bespoke workflow environment.
This release can be downloaded and installed now, and is delivered along with a comprehensive set of documentation and video tutorials. Certainly this release is a significant step towards the goal of the DDMoRe Consortium: sharing knowledge to improve drug development.
For further details please see the Press Release at: http://ddmore.eu/news/beta-release-ddmore-interoperability-framework